The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Recruiting now

LYL273 for Patients With Relapsed or Refractory mCRC

Phase 2 · 155 people · 5 sites in United States · Recruiting now

August 8, 2026
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

Phase 2 · randomised · 90 people · 20 sites in 9 countries · Recruiting now

August 8, 2026
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer

Phase 2 · 48 people · 1 site in China · Recruiting now

August 8, 2026
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer

Phase 2 · randomised · 50 people · 1 site in China · Recruiting now

August 8, 2026
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

Phase 2 · randomised · 80 people · 1 site in China · Recruiting now

August 8, 2026
AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM

Phase 2 · randomised · 73 people · 1 site in China · Recruiting now

August 8, 2026
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Phase 2 · 38 people · 4 sites in United States · Recruiting now

August 8, 2026
Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy

Phase 2 · randomised · 60 people · 1 site in United States · Recruiting now

August 8, 2026
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Phase 2 · 110 people · 1 site in United States · Recruiting now

August 8, 2026
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

Phase 2 · randomised · 346 people · 85 sites in 19 countries · Recruiting now

August 8, 2026